We are excited to announce that Silvia Gabanti, Arithmos’ Managing Director, will be speaking at Italian Pharmacovigilance Day 2021.
This year, the event will take place online on the 12th of October and focus on the following topics:
- Real-World Data, big data, and their impact on pharmacovigilance
- Regulatory evolution
- Technology evolution and its impact on pharmacovigilance
- Management of acquisitions/merges and product transfers
- Management of vendors and partner services
- When? 12th of October, 9:30 – 16:35 CEST
- Where? Online
- How to join? The registration is available at the Italian Pharmacovigilance Day website
Jointly with Antonella Ursini, Managing Director of seQure, Silvia will give a presentation titled “Pharmacovigilance and Technologies: an Insider Look at State of the Art, Challenges and Future” (original title – “Farmacovigilanza e tecnologia: uno sguardo dall’interno sullo stato dell’arte, sfide e futuro”).
About the presentation “Pharmacovigilance and Technologies: an Insider Look at State of the Art, Challenges, and Future”
Automation, advanced analytics, big data – these are just a few examples of the technology trends that have been reshaping pharmacovigilance function in the last years.
In order to get a competitive advantage from emerging technologies the Life Sciences companies are compelled to embrace the change and evolve both on the organizational and the technology side.
This presentation will be based upon our extensive customer survey conducted in order to understand the relationships between pharmacovigilance industry and technology.
As pharmacovigilance consultant and system integrator consultants, we will analyse the vision of the future of the pharmacovigilance professionals and evaluate technologies and business trends that may evolve to transform this space.
We will also cover the threats and the opportunities that the industry sees in digital transformation of pharmacovigilance.
To conclude, we will evaluate the strategies that can help to adopt new digital initiatives successfully and try to understand how pharmacovigilance staff could evolve to embrace the change.